Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients

NCT05806268 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05806268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05806268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
July 30, 2021
Completion date
March 28, 2022
Enrollment
214 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

braf v600 mutated metastatic melanoma